MCID: CRB138
MIFTS: 42

Core Binding Factor Acute Myeloid Leukemia malady

Categories: Cancer diseases

Aliases & Classifications for Core Binding Factor Acute Myeloid Leukemia

Aliases & Descriptions for Core Binding Factor Acute Myeloid Leukemia:

Name: Core Binding Factor Acute Myeloid Leukemia 25 69
Cbf Acute Myeloid Leukemia 25
Core-Binding Factor Aml 25
Cbf-Aml 25

Classifications:



Summaries for Core Binding Factor Acute Myeloid Leukemia

Genetics Home Reference : 25 Core binding factor acute myeloid leukemia (CBF-AML) is one form of a cancer of the blood-forming tissue (bone marrow) called acute myeloid leukemia. In normal bone marrow, early blood cells called hematopoietic stem cells develop into several types of blood cells: white blood cells (leukocytes) that protect the body from infection, red blood cells (erythrocytes) that carry oxygen, and blood cell fragments called platelets (thrombocytes) that are involved in blood clotting. In acute myeloid leukemia, the bone marrow makes large numbers of abnormal, immature white blood cells called myeloid blasts. Instead of developing into normal white blood cells, the myeloid blasts develop into cancerous leukemia cells. The large number of abnormal cells in the bone marrow interferes with the production of functional white blood cells, red blood cells, and platelets.

MalaCards based summary : Core Binding Factor Acute Myeloid Leukemia, also known as cbf acute myeloid leukemia, is related to leukemia and myeloid leukemia. An important gene associated with Core Binding Factor Acute Myeloid Leukemia is KIT (KIT Proto-Oncogene Receptor Tyrosine Kinase), and among its related pathways/superpathways are ERK Signaling and PEDF Induced Signaling. The drugs Cytarabine and Fludarabine have been mentioned in the context of this disorder. Affiliated tissues include myeloid, bone and bone marrow, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and cellular

Related Diseases for Core Binding Factor Acute Myeloid Leukemia

Diseases related to Core Binding Factor Acute Myeloid Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 61)
id Related Disease Score Top Affiliating Genes
1 leukemia 10.8
2 myeloid leukemia 10.8
3 malignant skin fibrous histiocytoma 10.2 HRAS KRAS
4 pseudomonas stutzeri infections 10.2 KRAS NRAS
5 dupuytren contracture 10.2 FLT3 KIT RUNX1
6 precursor t-lymphoblastic lymphoma/leukemia 10.2 HRAS KIT KRAS
7 choriocarcinoma 10.2 KIT WT1
8 kidney clear cell sarcoma 10.2 HRAS KIT KRAS
9 parotid gland adenoid cystic carcinoma 10.2 HRAS KIT NRAS
10 vulval paget's disease 10.2 HRAS KIT NRAS
11 arthus reaction 10.2 HRAS KIT KRAS
12 erythrocyte lactate transporter defect 10.2 HRAS KRAS NRAS
13 melanocytic nevus syndrome, congenital, somatic 10.2 HRAS KRAS NRAS
14 colorectal adenoma 10.2 FLT3 JAK2 RUNX1
15 vaginal yolk sac tumor 10.2 HRAS KIT NRAS
16 advanced sleep phase syndrome 10.2 HRAS KIT KRAS
17 hyperandrogenism due to cortisone reductase deficiency 10.2 FLT3 KIT WT1
18 ossifying fibromyxoid tumor 10.2 HRAS KRAS NRAS
19 retroperitoneal leiomyosarcoma 10.2 HRAS KIT NRAS
20 rdh12-related leber congenital amaurosis 10.2 KRAS NRAS
21 spongiotic dermatitis 10.2 HRAS KRAS NRAS
22 nelson syndrome 10.2 HRAS KIT NRAS
23 diffuse glomerulonephritis 10.2 KIT NRAS WT1
24 unilateral hemispheric polymicrogyria 10.1 CEBPA FLT3 KIT RUNX1
25 glycogen storage disease type 0 10.1 CEBPA FLT3 WT1
26 alpha chain disease 10.1 HRAS KIT NRAS
27 chronic venous insufficiency 10.1 HRAS KRAS
28 erythrocytosis, somatic 10.1 FLT3 JAK2 KIT
29 acute respiratory distress syndrome 10.1 CEBPA FLT3 JAK2 KIT
30 uterine corpus endometrial stromal sarcoma 10.1 HRAS KRAS WT1
31 neuromyelitis optica 10.1 FLT3 JAK2 KIT
32 gallbladder pleomorphic giant cell adenocarcinoma 10.1 HRAS NRAS WT1
33 malignant pleural solitary fibrous tumor 10.1 HRAS KIT KRAS NRAS
34 severe pre-eclampsia 10.1 HRAS KRAS
35 nephrolithiasis 10.1 CBL HRAS NRAS
36 joubert syndrome 18 10.1 HRAS KRAS NRAS
37 dental caries 10.1 HRAS KRAS WT1
38 nasal cavity disease 10.1 HRAS KRAS WT1
39 hormone producing pituitary cancer 10.0 KIT TLE1 WT1
40 agammaglobulinemia 8, autosomal dominant 10.0 CEBPA FLT3 JAK2 KIT KRAS
41 adducted thumbs dundar type 10.0 CBFB CSF1R FLT3 KIT RUNX1
42 acute hemorrhagic encephalitis 10.0 HRAS NRAS
43 van regemorter pierquin vamos syndrome 10.0 KIT MVP WT1
44 gestational choriocarcinoma 10.0 KIT TLE1 WT1
45 myeloproliferative neoplasm 9.9 CSF3 JAK2 RUNX1
46 bernard-soulier syndrome, type c 9.9 ABCG2 FLT3 KIT KRAS WT1
47 hematopoietic stem cell transplantation 9.9
48 systemic mastocytosis 9.9
49 mastocytosis 9.9
50 phosphoserine phosphatase deficiency 9.9 FLT3 MVP RUNX1 WT1

Graphical network of the top 20 diseases related to Core Binding Factor Acute Myeloid Leukemia:



Diseases related to Core Binding Factor Acute Myeloid Leukemia

Symptoms & Phenotypes for Core Binding Factor Acute Myeloid Leukemia

GenomeRNAi Phenotypes related to Core Binding Factor Acute Myeloid Leukemia according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-116 10.63 CBL FLT3
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-117 10.63 KRAS
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-145 10.63 CEBPA CBL WT1 KRAS FLT3
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-148 10.63 CEBPA CBL CSF3 NRAS
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-153 10.63 CBL
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-165 10.63 KRAS
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-171 10.63 FLT3
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-180 10.63 CBFB FLT3
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-187 10.63 FLT3
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-193 10.63 KRAS
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-204 10.63 CBFB CEBPA CBL CSF3 NRAS
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-216 10.63 KRAS
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-27 10.63 KRAS
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-28 10.63 NRAS
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-33 10.63 KRAS
16 Decreased shRNA abundance (Z-score < -2) GR00366-A-34 10.63 CSF3
17 Decreased shRNA abundance (Z-score < -2) GR00366-A-40 10.63 CBL
18 Decreased shRNA abundance (Z-score < -2) GR00366-A-48 10.63 CEBPA
19 Decreased shRNA abundance (Z-score < -2) GR00366-A-53 10.63 KRAS
20 Decreased shRNA abundance (Z-score < -2) GR00366-A-55 10.63 CBFB
21 Decreased shRNA abundance (Z-score < -2) GR00366-A-66 10.63 KRAS
22 Decreased shRNA abundance (Z-score < -2) GR00366-A-72 10.63 CEBPA NRAS
23 Decreased viability GR00055-A-2 10.13 KRAS HRAS
24 Decreased viability GR00106-A-0 10.13 KRAS
25 Decreased viability GR00173-A 10.13 FLT3
26 Decreased viability GR00221-A-1 10.13 CSF1R FLT3 KRAS NRAS HRAS KIT
27 Decreased viability GR00221-A-2 10.13 KRAS HRAS
28 Decreased viability GR00221-A-3 10.13 NRAS HRAS
29 Decreased viability GR00221-A-4 10.13 CSF1R FLT3
30 Decreased viability GR00301-A 10.13 KRAS KIT
31 Decreased viability GR00381-A-1 10.13 KRAS
32 Increased shRNA abundance (Z-score > 2) GR00366-A-100 9.95 CBFB WT1
33 Increased shRNA abundance (Z-score > 2) GR00366-A-102 9.95 FLT3
34 Increased shRNA abundance (Z-score > 2) GR00366-A-105 9.95 CBFB
35 Increased shRNA abundance (Z-score > 2) GR00366-A-115 9.95 FLT3
36 Increased shRNA abundance (Z-score > 2) GR00366-A-120 9.95 FLT3
37 Increased shRNA abundance (Z-score > 2) GR00366-A-121 9.95 CEBPA FLT3
38 Increased shRNA abundance (Z-score > 2) GR00366-A-122 9.95 CEBPA CBL CBFB FLT3 WT1
39 Increased shRNA abundance (Z-score > 2) GR00366-A-123 9.95 FLT3
40 Increased shRNA abundance (Z-score > 2) GR00366-A-13 9.95 CBFB
41 Increased shRNA abundance (Z-score > 2) GR00366-A-130 9.95 CBL
42 Increased shRNA abundance (Z-score > 2) GR00366-A-149 9.95 CBL
43 Increased shRNA abundance (Z-score > 2) GR00366-A-151 9.95 CBL
44 Increased shRNA abundance (Z-score > 2) GR00366-A-152 9.95 WT1
45 Increased shRNA abundance (Z-score > 2) GR00366-A-163 9.95 FLT3
46 Increased shRNA abundance (Z-score > 2) GR00366-A-169 9.95 CBFB
47 Increased shRNA abundance (Z-score > 2) GR00366-A-186 9.95 CBFB CBL
48 Increased shRNA abundance (Z-score > 2) GR00366-A-201 9.95 CBL
49 Increased shRNA abundance (Z-score > 2) GR00366-A-210 9.95 CBL
50 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.95 WT1
51 Increased shRNA abundance (Z-score > 2) GR00366-A-23 9.95 WT1
52 Increased shRNA abundance (Z-score > 2) GR00366-A-25 9.95 FLT3
53 Increased shRNA abundance (Z-score > 2) GR00366-A-30 9.95 WT1
54 Increased shRNA abundance (Z-score > 2) GR00366-A-35 9.95 WT1
55 Increased shRNA abundance (Z-score > 2) GR00366-A-42 9.95 CBFB
56 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.95 CEBPA CBL WT1
57 Increased shRNA abundance (Z-score > 2) GR00366-A-47 9.95 WT1
58 Increased shRNA abundance (Z-score > 2) GR00366-A-70 9.95 FLT3
59 Increased shRNA abundance (Z-score > 2) GR00366-A-79 9.95 CBFB
60 Increased shRNA abundance (Z-score > 2) GR00366-A-81 9.95 CBL
61 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.95 CEBPA CBFB WT1
62 Increased shRNA abundance (Z-score > 2) GR00366-A-88 9.95 CBFB
63 Increased cell migration GR00055-A-3 9.26 CSF1R CBL KRAS HRAS

MGI Mouse Phenotypes related to Core Binding Factor Acute Myeloid Leukemia:

44 (show all 19)
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.39 ABCG2 CBFB CEBPA CBL RUNX2 RUNX1
2 hematopoietic system MP:0005397 10.38 CBFB CEBPA CBL ABCG2 RUNX1 WT1
3 endocrine/exocrine gland MP:0005379 10.37 CBFB CEBPA CBL WT1 RUNX2 HRAS
4 homeostasis/metabolism MP:0005376 10.37 ABCG2 CBFB CEBPA CBL RUNX2 RUNX1
5 growth/size/body region MP:0005378 10.36 CBFB CEBPA CBL RUNX2 RUNX1 WT1
6 immune system MP:0005387 10.36 CBFB CEBPA CBL ABCG2 RUNX1 WT1
7 integument MP:0010771 10.31 CBFB CEBPA CBL ABCG2 RUNX2 KIT
8 cardiovascular system MP:0005385 10.28 CBL CBFB CEBPA RUNX2 RUNX1 WT1
9 mortality/aging MP:0010768 10.25 CBL CBFB CEBPA RUNX2 RUNX1 WT1
10 liver/biliary system MP:0005370 10.2 CBFB CEBPA CBL ABCG2 RUNX1 WT1
11 craniofacial MP:0005382 10.17 CBL CBFB RUNX2 HRAS CSF1R KRAS
12 no phenotypic analysis MP:0003012 10.15 CBFB CEBPA ABCG2 WT1 RUNX2 HRAS
13 neoplasm MP:0002006 10.1 CBFB CEBPA RUNX1 WT1 HRAS JAK2
14 normal MP:0002873 10.1 CBFB CEBPA ABCG2 RUNX1 WT1 HRAS
15 limbs/digits/tail MP:0005371 10.02 CBL CBFB RUNX2 CSF1R NRAS KRAS
16 renal/urinary system MP:0005367 9.8 ABCG2 CEBPA WT1 HRAS CSF3 KRAS
17 reproductive system MP:0005389 9.76 CBL RUNX2 WT1 CEBPA CSF1R JAK2
18 respiratory system MP:0005388 9.61 CBFB CEBPA CBL RUNX2 RUNX1 WT1
19 skeleton MP:0005390 9.32 CBL CBFB RUNX2 RUNX1 FLT3 HRAS

Drugs & Therapeutics for Core Binding Factor Acute Myeloid Leukemia

Drugs for Core Binding Factor Acute Myeloid Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 24)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cytarabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 147-94-4 6253
2
Fludarabine Approved Phase 4,Phase 2,Phase 1 21679-14-1, 75607-67-9 30751
3
Vidarabine Approved Phase 4,Phase 2,Phase 1 24356-66-9 32326 21704
4 Anti-Infective Agents Phase 4,Phase 3,Phase 1,Phase 2
5 Immunosuppressive Agents Phase 4,Phase 3,Phase 1,Phase 2
6 Antimetabolites Phase 4,Phase 3,Phase 1,Phase 2
7 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 1,Phase 2
8 Antiviral Agents Phase 4,Phase 3,Phase 1,Phase 2
9
Daunorubicin Approved Phase 3,Phase 1,Phase 2 20830-81-3 30323
10
Dasatinib Approved, Investigational Phase 3,Phase 2,Phase 1 302962-49-8 3062316
11 Topoisomerase Inhibitors Phase 3,Phase 1,Phase 2
12 Anti-Bacterial Agents Phase 3,Phase 1,Phase 2
13 Protein Kinase Inhibitors Phase 3,Phase 2,Phase 1
14 Antibiotics, Antitubercular Phase 3,Phase 1,Phase 2
15
Mitoxantrone Approved, Investigational Phase 2 65271-80-9 4212
16
Etoposide Approved Phase 2 33419-42-0 36462
17
Idarubicin Approved Phase 2,Phase 1 58957-92-9 42890
18
Busulfan Approved, Investigational Phase 2 55-98-1 2478
19
Lenograstim Approved Phase 2 135968-09-1
20
alvocidib Phase 2 131740-09-5 5287969
21 Analgesics Phase 2
22 Peripheral Nervous System Agents Phase 2
23 Adjuvants, Immunologic Phase 2
24 Etoposide phosphate Phase 2

Interventional clinical trials:

(show all 14)
id Name Status NCT ID Phase
1 Fludarabine and Cytarabine Versus High-dose Cytarabine for CBF-AML Recruiting NCT02926586 Phase 4
2 Timed-Sequential Induction in CBF-AML Completed NCT00428558 Phase 3
3 Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycel™) Recruiting NCT02013648 Phase 3
4 Autologous Hematopoietic Cell Transplantation for Core-binding Factor (CBF) Acute Myeloid Leukemia (AML) in the First Complete Remission (CR1) Unknown status NCT01146977 Phase 2
5 Study to Assess Dasatinib in Patients With Core Binding Factors Acute Myelogenous Leukemia Completed NCT02113319 Phase 2
6 Dasatinib (Sprycel™) in Patients With Newly Diagnosed Core Binding Factor (CBF) Acute Myeloid Leukemia (AML) Completed NCT00850382 Phase 1, Phase 2
7 Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Completed NCT00407966 Phase 2
8 Autologous Hematopoietic Cell Transplantation for Core-binding Factor Acute Myeloid Leukemia Recruiting NCT01050036 Phase 2
9 Fludarabine, Cytarabine, Filgrastim and Idarubicin in Core Binding Factor (CBF) Leukemias Recruiting NCT00801489 Phase 2
10 Combination Chemotherapy and Dasatinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Active, not recruiting NCT01238211 Phase 2
11 Dasatinib in Combination With Chemotherapy for Relapsed or Refractory Core Binding Factor Acute Myeloid Leukemia Recruiting NCT02680951 Phase 1
12 Genome Wide SNP Array-based Approach to Detect Micro-cytogenetic Lesions and KIT Mutation to Improve Treatment Outcomes in Patients With Core-binding Factor Positive Acute Myeloid Leukemia Unknown status NCT01066286
13 The Efficiency of CAMS (Chinese Academy of Medical Sciences)-2016 Trial for Pediatric Acute Myeloid Leukemia Recruiting NCT03173612
14 Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Recruiting NCT02971397

Search NIH Clinical Center for Core Binding Factor Acute Myeloid Leukemia

Genetic Tests for Core Binding Factor Acute Myeloid Leukemia

Anatomical Context for Core Binding Factor Acute Myeloid Leukemia

MalaCards organs/tissues related to Core Binding Factor Acute Myeloid Leukemia:

39
Myeloid, Bone, Bone Marrow, Eye

Publications for Core Binding Factor Acute Myeloid Leukemia

Articles related to Core Binding Factor Acute Myeloid Leukemia:

(show top 50) (show all 56)
id Title Authors Year
1
Significance of KIT exon 17 mutation depends on mutant level rather than positivity in core-binding factor acute myeloid leukemia. ( 26771813 )
2016
2
Prognostic Significance of KIT Mutations in Core-Binding Factor Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis. ( 26771376 )
2016
3
Comparison of Multiparameter Flow Cytometry Immunophenotypic Analysis and Quantitative RT-PCR for the Detection of Minimal Residual Disease of Core Binding Factor Acute Myeloid Leukemia. ( 27298396 )
2016
4
Predictive value of molecular remissions postconsolidation chemotherapy in patients with Core Binding Factor Acute Myeloid Leukemia (CBF-AML) - a single center analysis. ( 27597292 )
2016
5
Stem Cell Modeling of Core Binding Factor Acute Myeloid Leukemia. ( 26880987 )
2016
6
Comprehensive mutational profiling of core binding factor acute myeloid leukemia. ( 26980726 )
2016
7
Prognostic importance of c-kit mutations in core binding factor acute myeloid leukemia: A systematic review. ( 27613372 )
2016
8
Additional chromosomal abnormalities in core-binding factor acute myeloid leukemia. ( 26681050 )
2015
9
Core Binding Factor Acute Myeloid Leukemia: New Prognostic Categories and Therapeutic Opportunities. ( 26111469 )
2015
10
Complex karyotype, older age, and reduced first-line dose intensity determine poor survival in core binding factor acute myeloid leukemia patients with long-term follow-up. ( 25753065 )
2015
11
Incidences and Prognostic Impact of c-KIT, WT1, CEBPA, and CBL Mutations, and Mutations Associated With Epigenetic Modification in Core Binding Factor Acute Myeloid Leukemia: A Multicenter Study in a Korean Population. ( 25932436 )
2015
12
Dasatinib in high-risk core binding factor acute myeloid leukemia in first complete remission. A French Acute Myeloid leukemia Intergroup trial. ( 25715404 )
2015
13
High prognostic value of minimal residual disease detected by flow-cytometry-enhanced fluorescence in situ hybridization in core-binding factor acute myeloid leukemia (CBF-AML). ( 24844781 )
2014
14
Anthracycline dose intensification improves molecular response and outcome of patients treated for core binding factor acute myeloid leukemia. ( 24972769 )
2014
15
Core-binding factor acute myeloid leukemia in first relapse: a retrospective study from the French AML Intergroup. ( 25006122 )
2014
16
Prevalence and prognostic significance of c-KIT mutations in core binding factor acute myeloid leukemia: a comprehensive large-scale study from a single Chinese center. ( 25449688 )
2014
17
Core-binding factor acute myeloid leukemia: Heterogeneity, monitoring, and therapy. ( 25088818 )
2014
18
Prognosis and monitoring of core-binding factor acute myeloid leukemia: current and emerging factors. ( 25348871 )
2014
19
Population-based disparities in survival among patients with core-binding factor acute myeloid leukemia: a SEER database analysis. ( 24793731 )
2014
20
Excess treatment reduction including anthracyclines results in higher incidence of relapse in core binding factor acute myeloid leukemia in children. ( 23677335 )
2013
21
Core-binding factor acute myeloid leukemia: can we improve on HiDAC consolidation? ( 24319183 )
2013
22
Core-binding factor acute myeloid leukemia in pediatric patients enrolled in the AIEOP AML 2002/01 trial: screening and prognostic impact of c-KIT mutations. ( 24226631 )
2013
23
Prognosis of patients with core binding factor acute myeloid leukemia after first relapse. ( 23716553 )
2013
24
Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia. ( 23321257 )
2013
25
KIT D816 mutation associates with adverse outcomes in core binding factor acute myeloid leukemia, especially in the subgroup with RUNX1/RUNX1T1 rearrangement. ( 23053179 )
2013
26
The importance of relative mutant level for evaluating impact on outcome of KIT, FLT3 and CBL mutations in core-binding factor acute myeloid leukemia. ( 23783394 )
2013
27
Therapy of core binding factor acute myeloid leukemia: incremental improvements toward better long-term results. ( 23266036 )
2013
28
Core binding factor acute myeloid leukemia: the impact of age, leukocyte count, molecular findings, and minimal residual disease. ( 23646898 )
2013
29
A genome-wide single-nucleotide polymorphism-array can improve the prognostic stratification of the core binding factor acute myeloid leukemia. ( 22886749 )
2012
30
Systemic mastocytosis is uncommon in KIT D816V mutation positive core-binding factor acute myeloid leukemia. ( 22145956 )
2012
31
Impact of residual normal metaphases in core binding factor acute myeloid leukemia. ( 21928314 )
2012
32
High-resolution genomic profiling of adult and pediatric core-binding factor acute myeloid leukemia reveals new recurrent genomic alterations. ( 22234698 )
2012
33
Prognostic impact of c-KIT mutations in core binding factor acute myeloid leukemia. ( 21715005 )
2011
34
Core binding factor acute myeloid leukemia (CBF-AML) in MAcxico: a single institution experience. ( 21574542 )
2011
35
Treatment strategies in patients with core-binding factor acute myeloid leukemia. ( 21755276 )
2011
36
Core-binding factor acute myeloid leukemia. ( 22032582 )
2011
37
Peripheral blasts on day 21 of induction chemotherapy in a patient with core binding factor acute myeloid leukemia: more than meets the eye. ( 20709669 )
2010
38
Monitoring of minimal residual disease in patients with core binding factor acute myeloid leukemia and the impact of C-KIT, FLT3, and JAK2 mutations on clinical outcome. ( 19603346 )
2009
39
Rapid detection of KIT mutations in core-binding factor acute myeloid leukemia using high-resolution melting analysis. ( 19644024 )
2009
40
Hematopoietic stem cell transplantation for core binding factor acute myeloid leukemia: t(8;21) and inv(16) represent different clinical outcomes. ( 19126873 )
2009
41
Core binding factor acute myeloid leukemia (CBF-AML): is high-dose Ara-C (HDAC) consolidation as effective as you think? ( 19468270 )
2009
42
A >or=1 log rise in RQ-PCR transcript levels defines molecular relapse in core binding factor acute myeloid leukemia and predicts subsequent morphologic relapse. ( 18297529 )
2008
43
Histone deacetylase inhibitor romidepsin has differential activity in core binding factor acute myeloid leukemia. ( 18981008 )
2008
44
Advances in molecular genetics and treatment of core-binding factor acute myeloid leukemia. ( 18841055 )
2008
45
Core binding factor acute myeloid leukemia. ( 18692691 )
2008
46
Cooperating mutations of receptor tyrosine kinases and Ras genes in childhood core-binding factor acute myeloid leukemia and a comparative analysis on paired diagnosis and relapse samples. ( 17960171 )
2008
47
Autologous stem cell transplantation with PCR-negative graft would be associated with a favorable outcome in core-binding factor acute myeloid leukemia. ( 18940681 )
2008
48
Gene-expression profiling identifies distinct subclasses of core binding factor acute myeloid leukemia. ( 17485551 )
2007
49
Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML). ( 16598313 )
2006
50
Core binding factor acute myeloid leukemia. ( 16728942 )
2006

Variations for Core Binding Factor Acute Myeloid Leukemia

Expression for Core Binding Factor Acute Myeloid Leukemia

Search GEO for disease gene expression data for Core Binding Factor Acute Myeloid Leukemia.

Pathways for Core Binding Factor Acute Myeloid Leukemia

Pathways related to Core Binding Factor Acute Myeloid Leukemia according to GeneCards Suite gene sharing:

(show top 50) (show all 88)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.89 CBL CSF1R CSF3 FLT3 HRAS JAK2
2
Show member pathways
13.68 CEBPA CSF1R CSF3 FLT3 HRAS JAK2
3
Show member pathways
13.57 CBL CSF1R FLT3 HRAS JAK2 KIT
4
Show member pathways
13.34 CEBPA CSF1R CSF3 FLT3 HRAS JAK2
5
Show member pathways
13.32 CSF1R CSF3 HRAS JAK2 KIT KRAS
6
Show member pathways
13.26 CBL CSF1R CSF3 FLT3 HRAS JAK2
7
Show member pathways
13.23 CBL CSF1R FLT3 HRAS KIT KRAS
8
Show member pathways
13.07 CSF1R HRAS JAK2 KIT KRAS NRAS
9
Show member pathways
13.04 CBL HRAS JAK2 KIT KRAS NRAS
10
Show member pathways
12.92 CBL HRAS JAK2 KRAS NRAS
11
Show member pathways
12.92 CBL HRAS JAK2 KIT KRAS NRAS
12
Show member pathways
12.84 CBL HRAS JAK2 KRAS NRAS
13
Show member pathways
12.76 CSF1R HRAS KIT KRAS NRAS
14
Show member pathways
12.76 CBL HRAS KIT KRAS NRAS
15
Show member pathways
12.59 CBL HRAS JAK2 KRAS NRAS
16 12.56 CBL CEBPA JAK2 KIT RUNX1
17
Show member pathways
12.53 CBL HRAS KRAS NRAS
18
Show member pathways
12.5 CBL HRAS JAK2 KRAS NRAS
19
Show member pathways
12.47 CBL FLT3 HRAS KRAS NRAS
20 12.46 CBL CSF1R HRAS KIT
21
Show member pathways
12.46 CBL HRAS KRAS NRAS
22
Show member pathways
12.43 HRAS KIT KRAS NRAS
23
Show member pathways
12.43 CBL CEBPA HRAS JAK2
24
Show member pathways
12.42 CBL HRAS KRAS NRAS
25 12.4 CSF1R CSF3 HRAS JAK2 KIT KRAS
26
Show member pathways
12.39 HRAS KIT KRAS NRAS
27
Show member pathways
12.38 CBL HRAS KRAS NRAS
28
Show member pathways
12.36 CBL HRAS KRAS NRAS
29
Show member pathways
12.34 CBL HRAS KRAS NRAS
30 12.33 CBL HRAS KRAS NRAS
31
Show member pathways
12.33 HRAS JAK2 KRAS NRAS
32
Show member pathways
12.3 CBL HRAS KRAS NRAS
33
Show member pathways
12.25 CBL HRAS JAK2 KRAS NRAS
34
Show member pathways
12.25 CBL FLT3 HRAS JAK2 KRAS NRAS
35 12.22 CBL HRAS JAK2 KRAS
36
Show member pathways
12.21 CBL HRAS JAK2 KIT
37 12.21 CBL CEBPA CSF1R FLT3 HRAS KIT
38
Show member pathways
12.17 CBL HRAS KRAS NRAS
39 12.14 CSF1R HRAS KRAS NRAS
40 12.12 HRAS JAK2 KRAS NRAS
41
Show member pathways
12.11 HRAS JAK2 KRAS NRAS
42
Show member pathways
12.1 CBL HRAS JAK2 KRAS
43
Show member pathways
12.09 CBL HRAS KRAS NRAS
44 12.03 CBL CSF1R FLT3 JAK2 KIT
45 12.01 CSF3 FLT3 KIT
46 12.01 HRAS KRAS NRAS
47 12 HRAS KRAS NRAS
48
Show member pathways
12 CBL HRAS KRAS NRAS RUNX1
49 11.99 HRAS KRAS NRAS
50 11.99 CEBPA CSF1R FLT3 RUNX1 RUNX2 WT1

GO Terms for Core Binding Factor Acute Myeloid Leukemia

Biological processes related to Core Binding Factor Acute Myeloid Leukemia according to GeneCards Suite gene sharing:

(show all 32)
id Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 9.98 CEBPA CSF1R HRAS JAK2 WT1
2 positive regulation of gene expression GO:0010628 9.92 HRAS KIT KRAS RUNX2 TLE1
3 axon guidance GO:0007411 9.89 CSF1R HRAS KRAS NRAS
4 positive regulation of cell migration GO:0030335 9.87 CSF1R HRAS JAK2 KIT
5 protein autophosphorylation GO:0046777 9.86 CSF1R FLT3 JAK2 KIT
6 peptidyl-tyrosine phosphorylation GO:0018108 9.85 CSF1R FLT3 JAK2 KIT
7 MAPK cascade GO:0000165 9.83 HRAS JAK2 KIT KRAS NRAS
8 male gonad development GO:0008584 9.82 CBL KIT WT1
9 ossification GO:0001503 9.8 CBFB RUNX1 RUNX2
10 positive regulation of MAPK cascade GO:0043410 9.79 FLT3 HRAS KIT
11 Ras protein signal transduction GO:0007265 9.77 HRAS KRAS NRAS
12 positive regulation of MAP kinase activity GO:0043406 9.71 FLT3 HRAS KIT KRAS
13 cell maturation GO:0048469 9.69 CBFB CEBPA RUNX2
14 ERBB2 signaling pathway GO:0038128 9.67 HRAS KRAS NRAS
15 epidermal growth factor receptor signaling pathway GO:0007173 9.67 CBL HRAS KRAS NRAS
16 regulation of long-term neuronal synaptic plasticity GO:0048169 9.65 HRAS KRAS
17 positive regulation of tyrosine phosphorylation of Stat5 protein GO:0042523 9.65 JAK2 KIT
18 macrophage differentiation GO:0030225 9.65 CEBPA CSF1R
19 positive regulation of tyrosine phosphorylation of Stat3 protein GO:0042517 9.65 CSF1R JAK2 KIT
20 hemopoiesis GO:0030097 9.65 CSF1R FLT3 KIT RUNX1 RUNX2
21 positive regulation of actin cytoskeleton reorganization GO:2000251 9.64 CSF3 HRAS
22 mast cell degranulation GO:0043303 9.63 CBL KIT
23 cellular response to cytokine stimulus GO:0071345 9.63 CSF1R CSF3 FLT3
24 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.62 CSF1R FLT3 JAK2 KIT
25 response to isolation stress GO:0035900 9.61 HRAS KRAS
26 granulocyte differentiation GO:0030851 9.61 CEBPA CSF3
27 myeloid progenitor cell differentiation GO:0002318 9.58 FLT3 KIT
28 positive regulation of cell proliferation GO:0008284 9.56 CSF1R CSF3 FLT3 HRAS JAK2 KIT
29 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.55 CBL CSF3 FLT3 JAK2 KIT
30 cytokine-mediated signaling pathway GO:0019221 9.17 CEBPA CSF1R CSF3 FLT3 JAK2 KIT
31 positive regulation of transcription from RNA polymerase II promoter GO:0045944 10.08 CBFB CEBPA CSF3 HRAS RUNX1 RUNX2
32 transcription from RNA polymerase II promoter GO:0006366 10.03 CBFB CEBPA RUNX1 RUNX2 WT1

Molecular functions related to Core Binding Factor Acute Myeloid Leukemia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 transcription factor activity, sequence-specific DNA binding GO:0003700 9.8 CBFB CBL CEBPA RUNX1 RUNX2 WT1
2 ATP binding GO:0005524 9.8 ABCG2 CSF1R FLT3 JAK2 KIT RUNX1
3 nucleotide binding GO:0000166 9.35 HRAS JAK2 KIT KRAS NRAS
4 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.33 CSF1R FLT3 KIT
5 protein tyrosine kinase activity GO:0004713 8.92 CSF1R FLT3 JAK2 KIT

Sources for Core Binding Factor Acute Myeloid Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....